Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus

Journal of Virology

Volumn 83, Issue 14, 2009, Pages 7285-7295

  Safronetz, David ^a,b,f   Hegde, Nagendra R ^c,g   Ebihara, Hideki ^b,d,f   Denton, Michael ^c   Kobinger, Gary P ^a,b   St Jeor, Stephen ^e   Feldmann, Heinz ^a,b,f   Johnson, David C ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g Bharat Biotech Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR GLYCOPROTEIN C; ADENOVIRUS VECTOR GLYCOPROTEIN N; ADENOVIRUS VECTOR GLYCOPROTEIN N ADENOVIRUS VECTOR GLYCOPROTEIN C CONJUGATE; ADENOVIRUS VECTOR NUCLEOCAPSID PROTEIN; NUCLEOCAPSID PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ANDES VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HANTAVIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; SYRIAN HAMSTER; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VIRUS INFECTION; VIRUS NUCLEOCAPSID;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GLYCOPROTEINS; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; MESOCRICETUS; MICE; MICE, INBRED BALB C; VACCINATION; VIRAL CORE PROTEINS; VIRAL VACCINES;

ADENOVIRIDAE; ANDES VIRUS; ANIMALIA; CRICETINAE; HANTAVIRUS; MESOCRICETUS AURATUS; MUS; RODENTIA;

EID: 67650383799     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00373-09     Document Type: Article

References (53)

1. Bangari, D. S., and S. K. Mittal. 2006. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6:215-226.
2. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, B. Korioth-Schmitz, M. H. Newberg, D. A. Gorgone, M. A. Lifton, D. L. Panicali, G. J. Nabel, N. L. Letvin, and J. Goudsmit. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
3. Bharadwaj, M., C. R. Lyons, I. A. Wortman, and B. Hjelle. 1999. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 17:2836-2843.
4. Bharadwaj, M., K. Mirowsky, C. Ye, J. Botten, B. Masten, J. Yee, C. R. Lyons, and B. Hjelle. 2002. Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). J. Gen. Virol. 83:1745-1751.
5. Bharadwaj, M., R. Nofchissey, D. Goade, F. Koster, and B. Hjelle. 2000. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 182:43-48.
6. Carroll, D. S., J. N. Mills, J. M. Montgomery, D. G. Bausch, P. J. Blair, J. P. Burans, V. Felices, A. Gianella, N. Iihoshi, S. T. Nichol, J. G. Olson, D. S. Rogers, M. Salazar, and T. G. Ksiazek. 2005. Hantavirus pulmonary syndrome in Central Bolivia: relationships between reservoir hosts, habitats, and viral genotypes. Am. J. Trop. Med. Hyg. 72:42-46.
7. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S. Dubey, D. M. Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D. Williams, W. Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long, W. Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X. Liang, R. Youil, M. Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
8. Childs, J. E., T. G. Ksiazek, C. F. Spiropoulou, J. W. Krebs, S. Morzunov, G. O. Maupin, K. L. Gage, P. E. Rollin, J. Sarisky, R. E. Enscore, et al. 1994. Serologic and genetic identification of Peromyscus maniculatus as the primary rodent reservoir for a new hantavirus in the southwestern United States. J. Infect. Dis. 169:1271-1280.
9. Croyle, M. A., A. Patel, K. N. Tran, M. Gray, Y. Zhang, J. E. Strong, H. Feldmann, and G. P. Kobinger. 2008. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3:e3548.
10. Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J. W. Hooper. 2003. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J. Virol. 77:9894-9905.
11. Enria, D. A., A. M. Briggiler, N. Pini, and S. Levis. 2001. Clinical manifestations of New World hantaviruses. Curr. Top. Microbiol. Immunol. 256:117-134.
12. Feldmann, H., A. Sanchez, S. Morzunov, C. F. Spiropoulou, P. E. Rollin, T. G. Ksiazek, C. J. Peters, and S. T. Nichol. 1993. Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome. Virus Res. 30:351-367.
13. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
14. Hegde, N. R., C. Dunn, D. M. Lewinsohn, M. A. Jarvis, J. A. Nelson, and D. C. Johnson. 2005. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J. Exp. Med. 202:1109-1119.
15. Hitt, M., A. J. Bett, C. L. Addison, L. Prevec, and F. L. Graham. 1995. Techniques for human adenovirus vector construction and characterization. Methods Mol. Genet. 78:13-30.
16. Hooper, J. W., D. M. Custer, J. Smith, and V. Wahl-Jensen. 2006. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347:208-216.
17. Hooper, J. W., A. M. Ferro, and V. Wahl-Jensen. 2008. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J. Virol. 82:1332-1338.
18. Hooper, J. W., K. I. Kamrud, F. Elgh, D. Custer, and C. S. Schmaljohn. 1999. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255:269-278.
19. Hooper, J. W., T. Larsen, D. M. Custer, and C. S. Schmaljohn. 2001. A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6-14.
20. Hooper, J. W., and D. Li. 2001. Vaccines against hantaviruses. Curr. Top. Microbiol. Immunol. 256:171-191.
21. Hutchinson, L., H. Browne, V. Wargent, N. Davis-Poynter, S. Primorac, K. Goldsmith, A. C. Minson, and D. C. Johnson. 1992. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J. Virol. 66:2240-2250.
22. Jonsson, C. B., J. Hooper, and G. Mertz. 2008. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 78:162-169.
23. Kamrud, K. I., J. W. Hooper, F. Elgh, and C. S. Schmaljohn. 1999. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology 263:209-219.
24. Khaiboullina, S. F., S. P. Morzunov, and S. C. St. Jeor. 2005. Hantaviruses: molecular biology, evolution and pathogenesis. Curr. Mol. Med. 5:773-790.
25. Kobinger, G. P., H. Feldmann, Y. Zhi, G. Schumer, G. Gao, F. Feldmann, S. Jones, and J. M. Wilson. 2006. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346:394-401.
26. Lemckert, A. A., S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Lifton, J. Goudsmit, M. J. Havenga, and D. H. Barouch. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 79:9694-9701.
27. Levis, S., J. E. Rowe, S. Morzunov, D. A. Enria, and S. St. Jeor. 1997. New hantaviruses causing hantavirus pulmonary syndrome in central Argentina. Lancet 349:998-999.
28. Lopez, N., P. Padula, C. Rossi, M. E. Lazaro, and M. T. Franze-Fernandez. 1996. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 220:223-226.
29. Lundkvist, A., H. Kallio-Kokko, K. B. Sjolander, H. Lankinen, B. Niklasson, A. Vaheri, and O. Vapalahti. 1996. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology 216:397-406.
30. Maeda, K., K. West, D. Hayasaka, F. A. Ennis, and M. Terajima. 2005. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol. 18:657-667.
31. Maes, P., J. Clement, I. Gavrilovskaya, and M. Van Ranst. 2004. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 17:481-497.
32. Maes, P., J. Clement, and M. Van Ranst. 2009. Recent approaches in hantavirus vaccine development. Expert Rev. Vaccines 8:67-76.
33. Matthews, D. A., D. Cummings, C. Evelegh, F. L. Graham, and L. Prevec. 1999. Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J. Gen. Virol. 80:345-353.
34. McClain, D. J., P. L. Summers, S. A. Harrison, A. L. Schmaljohn, and C. S. Schmaljohn. 2000. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 60:77-85.
35. Meissner, J. D., J. E. Rowe, M. K. Borucki, and S. C. St. Jeor. 2002. Complete nucleotide sequence of a Chilean hantavirus. Virus Res. 89:131-143.
36. Mertz, G. J., L. Miedzinski, D. Goade, A. T. Pavia, B. Hjelle, C. O. Hansbarger, H. Levy, F. T. Koster, K. Baum, A. Lindemulder, W. Wang, L. Riser, H. Fernandez, and R. J. Whitley. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39:1307-1313.
37. Mishell, R. I., J. M. Shiigi, B. B. Mishell, K. H. Grabstein, and S. M. Shiigi. 1980. Prevention of the immunosuppressive effects of glucocorticosteroids by cell-free factors from adjuvant-activated accessory cells. Immunopharmacology 2:233-245.
38. Nichol, S. T., R. M. Elliot, A. Goldbach, C. S. Plyusnin, C. S. Schmaljohn, and R. B. Tesh. 2005. Bunyaviridae, p. 695-716. In C. M. Fauquet, M. A. Mayo, J. Manilfoff, U. Desselberger, and L. A. Ball (ed.), Virus taxonomy: VIIth report of the International Committtee on Taxonomy of Viruses. Academic Press, San Diego, CA.
39. Ogino, M., H. Ebihara, B. H. Lee, K. Araki, A. Lundkvist, Y. Kawaoka, K. Yoshimatsu, and J. Arikawa. 2003. Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab Immunol. 10:154-160.
40. Pensiero, M. N., G. B. Jennings, C. S. Schmaljohn, and J. Hay. 1988. Expression of the hantaan virus M genome segment by using a vaccinia virus recombinant. J. Virol. 62:696-702.
41. Ryckman, B. J., B. L. Rainish, M. C. Chase, J. A. Borton, J. A. Nelson, M. A. Jarvis, and D. C. Johnson. 2008. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82:60-70.
42. Schmaljohn, C. S., Y. K. Chu, A. L. Schmaljohn, and J. M. Dalrymple. 1990. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J. Virol. 64:3162-3170.
43. Schmaljohn, C. S., S. E. Hasty, and J. M. Dalrymple. 1992. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 10:10-13.
44. Schmaljohn, C. S., and S. T. Nichol. 2007. Bunyaviridae, p. 1742-1789. In D. M. Knipe and P. A. Howley (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
45. Schonrich, G., A. Rang, N. Lutteke, M. J. Raftery, N. Charbonnel, and R. G. Ulrich. 2008. Hantavirus-induced immunity in rodent reservoirs and humans. Immunol. Rev. 225:163-189.
46. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
47. Sridhar, S., A. Reyes-Sandoval, S. J. Draper, A. C. Moore, S. C. Gilbert, G. P. Gao, J. M. Wilson, and A. V. Hill. 2008. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82:3822-3833.
48. Tatsis, N., and H. C. Ertl. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629.
49. Tomazin, R., A. B. Hill, P. Jugovic, I. York, P. van Endert, H. L. Ploegh, D. W. Andrews, and D. C. Johnson. 1996. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 15:3256-3266.
50. Ulrich, R., A. Lundkvist, H. Meisel, D. Koletzki, K. B. Sjolander, H. R. Gelderblom, G. Borisova, P. Schnitzler, G. Darai, and D. H. Kruger. 1998. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 16:272-280.
51. Wisner, T., C. Brunetti, K. Dingwell, and D. C. Johnson. 2000. The extracellular domain of herpes simplex virus gE is sufficient for accumulation at cell junctions but not for cell-to-cell spread. J. Virol. 74:2278-2287.
52. Xu, X., S. L. Ruo, J. B. McCormick, and S. P. Fisher-Hoch. 1992. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am. J. Trop. Med. Hyg. 47:397-404.
53. York, I. A., C. Roop, D. W. Andrews, S. R. Riddell, F. L. Graham, and D. C. Johnson. 1994. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525-535.